Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium.
PMID: 28760216 ·
J, o, n, a, t, h, a, n, , H, , S, e, l, t, z, e, r, ;, , T, e, d, , H, e, i, s, e, ;, , P, e, t, e, r, , C, a, r, s, o, n, ;, , D, a, n, i, e, l, , C, a, n, o, s, ;, , J, o, , C, a, r, o, l, , H, i, a, t, t, ;, , P, a, s, c, a, l, , V, r, a, n, c, k, x, ;, , T, h, o, m, a, s, , C, h, r, i, s, t, e, n, ;, , D, o, n, a, l, d, , E, , C, u, t, l, i, p
Anzeige
Zusammenfassung
This white paper provides a summary of presentations, discussions and conclusions of a Thinktank entitled "The Role of Endpoint Adjudication in Medical Device Clinical Trials". The think tank was cosponsored by the Cardiac Safety Research Committee, MDEpiNet and the US Food and Drug Administration (FDA) and was convened at the FDA's White Oak headquarters on March 11, 2016. Attention was focused on tailoring best practices for evaluation of endpoints in medical device clinical trials, practical
Anzeige
Offizielle Quelle
Auf PubMed ansehen →Daten aus PubMed / NCBI. Den Volltext und die aktuellsten Informationen finden Sie stets im offiziellen Eintrag.